注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Arvinas Inc是一家处于临床阶段的生物技术公司。该公司从事降解致病蛋白质的疗法的发现、开发和商业化。该公司利用其蛋白分解靶向嵌合体(PROTAC)发现引擎这一技术平台来设计PROTAC靶向蛋白降解剂,旨在利用人体自身的天然蛋白处理系统来选择性地清除致病蛋白。其三个候选产品包括ARV-110、ARV-471和ARV-766。该公司开发的ARV-110是一种针对雄性激素受体蛋白(AR)的PROTAC蛋白降解剂,用于治疗男性转移性耐阉割前列腺癌(mCRPC)。该公司开发了ARV-471,一种针对雌激素受体蛋白(ER)的PROTAC蛋白降解剂,用于治疗局部晚期或转移性ER阳性、HER2阴性乳腺癌患者。该公司开发了ARV-766,一种PROTAC蛋白降解剂,用于治疗男性mCRPC患者。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Linda Cathavina Bain | 53 | 2020 | Independent Director |
Sunil Agarwal | 53 | 2023 | Independent Director |
Bradley T. Hyman | - | 2022 | Member of Scientific Advisory Board |
John G. Houston | 63 | 2017 | Chairperson, CEO & President |
John D. Young | 58 | 2022 | Independent Director |
Everett V. Cunningham | 57 | 2022 | Independent Director |
Michelle Arkin | - | 2023 | Member of Scientific Advisory Board |
Susan Kaech | - | 2022 | Member of Scientific Advisory Board |
Edward Moore Kennedy | 62 | 2018 | Independent Director |
Benjamin G. Neel | - | 2019 | Member of Scientific Advisory Board |
Laurie Smaldone Alsup | 69 | 2019 | Independent Director |
Leslie V. Norwalk | 58 | 2019 | Independent Director |
Adam L. Boxer | - | 2019 | Member of Scientific Advisory Board |
Briggs W. Morrison | 63 | 2018 | Lead Independent Director |
Wendy L. Dixon | 68 | 2020 | Independent Director |
Lillian L. Siu | - | 2019 | Member of Scientific Advisory Board |
Lennart Mucke | - | 2019 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核